Breaking News Instant updates and real-time market news.

DVAX

Dynavax

$6.90

2.4 (53.33%)

17:12
03/01/17
03/01
17:12
03/01/17
17:12

Senvest Management reports 4.85% passive stake in Dynavax

  • 10

    Aug

DVAX Dynavax
$6.90

2.4 (53.33%)

04/28/16
RBCM
04/28/16
DOWNGRADE
RBCM
Sector Perform
Dynavax downgraded on drug safety concerns at RBC Capital
As noted earlier, RBC Capital downgraded Dynavax to Sector Perform from Outperform, The firm cited concerns about the safety of the company's Heplisav-B drug as the reason for its downgrade. RBC says that the FDA's decision to request individual trial data instead of the integrated dataset shows that the agency's scrutiny of the drug's safety has increased. Target to $17 from $48.
09/06/16
WBLR
09/06/16
NO CHANGE
WBLR
Outperform
FDA panel cancelation positive for Dynavax, says William Blair
William Blair analyst Y. Katherine Xu views the FDA's decision to canceled the November 16 Vaccines and Related Biological Products Advisory Committee meeting for Heplisav as a net positive for Dynavax. The agency's decision to move straight to the PDUFA date suggests that the Heplisav package is "sufficiently strong and adequate to warrant approval in the absence of a panel," Xu tells investors in a research note. She keeps an Outperform rating on Dynavax. The stock is up 19% to $13.00 in pre-market trading.
11/14/16
COWN
11/14/16
NO CHANGE
Target $45
COWN
Outperform
Dynavax's Heplisav may still have a path forward, says Cowen
Cowen analyst Phil Nadeau called the CRL issued to Dynavax regarding its Biologics License Application for Heplisav-B "disappointing and concerning," but also noted that the FDA did not request new trials. While the CRL will push approval until late 2017, in a best case scenario, there may still be a path forward for approval of the drug, said Nadeau, who added that he thinks the stock now looks undervalued. The analyst has an Outperform rating and $45 price target on Dynavax shares.
11/15/16
WBLR
11/15/16
NO CHANGE
Target $17
WBLR
Outperform
William Blair still sees 'good chance' for approval of Dynavax's Heplisav
William Blair analyst Y. Katherine Xu lowered her price target for Dynavax Technologies to $17 from $45 after the company received a second Complete Response Letter from the FDA for the Heplisav Biologics License Application. There is still a "good chance" for Heplisav to garner eventual approval, Xu tells investors in a research note. The lack of apparent concerns regarding rare serious autoimmune events is a plus, the analyst contends. Xu keeps an Outperform rating on Dynavax. She points out the company's immuno-oncology program SD-101 is reading out substantial data starting in 2017. Dynavax closed yesterday down 65% to $4.10.

TODAY'S FREE FLY STORIES

KO

Coca-Cola

$45.71

-0.84 (-1.80%)

08:46
11/20/17
11/20
08:46
11/20/17
08:46
Recommendations
Coca-Cola analyst commentary  »

Coca-Cola investor day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$40.82

8.97 (28.16%)

08:45
11/20/17
11/20
08:45
11/20/17
08:45
Recommendations
Foot Locker analyst commentary  »

Foot Locker price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:45
11/20/17
11/20
08:45
11/20/17
08:45
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

JNJ

Johnson & Johnson

$138.00

-0.87 (-0.63%)

08:43
11/20/17
11/20
08:43
11/20/17
08:43
Hot Stocks
EU extends license for Janssen's Zytiga plus prednisone »

Janssen-Cilag…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

LIVN

LivaNova

$84.32

0.04 (0.05%)

08:42
11/20/17
11/20
08:42
11/20/17
08:42
Recommendations
LivaNova analyst commentary  »

LivaNova received fair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 01

    Dec

MNST

Monster Beverage

$62.17

0.17 (0.27%)

, KO

Coca-Cola

$45.71

-0.84 (-1.80%)

08:40
11/20/17
11/20
08:40
11/20/17
08:40
Downgrade
Monster Beverage, Coca-Cola rating change  »

Monster Beverage…

MNST

Monster Beverage

$62.17

0.17 (0.27%)

KO

Coca-Cola

$45.71

-0.84 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NQ

NQ Mobile

$4.05

-0.05 (-1.22%)

08:40
11/20/17
11/20
08:40
11/20/17
08:40
Hot Stocks
NQ Mobile provides update on FL Mobile Divestment »

NQ Mobile provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENSG

Ensign Group

$23.77

0.22 (0.93%)

08:38
11/20/17
11/20
08:38
11/20/17
08:38
Recommendations
Ensign Group analyst commentary  »

Ensign Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRVL

Marvell

$20.29

0.03 (0.15%)

, CAVM

Cavium

$75.83

-0.47 (-0.62%)

08:37
11/20/17
11/20
08:37
11/20/17
08:37
Hot Stocks
Marvell: Cavium deal doesn't include divestitures, changes to Cavium's portfolio »

On the conference call…

MRVL

Marvell

$20.29

0.03 (0.15%)

CAVM

Cavium

$75.83

-0.47 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

BKS

Barnes & Noble

$7.45

0.35 (4.93%)

08:35
11/20/17
11/20
08:35
11/20/17
08:35
Hot Stocks
Barnes & Noble announces Black Friday weekend deals »

Barnes & Noble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

ARAY

Accuray

$4.80

-0.1 (-2.04%)

08:35
11/20/17
11/20
08:35
11/20/17
08:35
Technical Analysis
Technical View: Accuray rallies in pre-market »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNUS

Genius Brands

$2.88

0.02 (0.70%)

08:34
11/20/17
11/20
08:34
11/20/17
08:34
Hot Stocks
Genius Brands signs multiple content sales deals for children's programming »

Genius Brands expands the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$34.95

-0.33 (-0.94%)

08:34
11/20/17
11/20
08:34
11/20/17
08:34
Initiation
Aimmune initiated  »

Aimmune initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

WOR

Worthington

$40.24

0.03 (0.07%)

08:33
11/20/17
11/20
08:33
11/20/17
08:33
Hot Stocks
WAVE to sell EMEA, Pacific Rim units »

Worthington (WOR)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTIV

On Track Innovations

$1.13

-0.01 (-0.88%)

08:32
11/20/17
11/20
08:32
11/20/17
08:32
Hot Stocks
On Track Innovations: UNO 6 selected by CityEV as cashless payment solution »

On Track Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MDSO

Medidata

$68.64

-0.85 (-1.22%)

08:32
11/20/17
11/20
08:32
11/20/17
08:32
Hot Stocks
Medidata, MEL MEDICAL announce multi-year Medidata eTMF agreement »

Medidata announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

PNTR

Pointer Telocation

$17.55

-0.2 (-1.13%)

08:30
11/20/17
11/20
08:30
11/20/17
08:30
Downgrade
Pointer Telocation rating change  »

Pointer Telocation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZH

Beazer Homes

$20.50

0.04 (0.20%)

08:29
11/20/17
11/20
08:29
11/20/17
08:29
Recommendations
Beazer Homes analyst commentary  »

Beazer Homes price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:28
11/20/17
11/20
08:28
11/20/17
08:28
Conference/Events
The Board of Governors of the Federal Reserve System holds a closed meeting »

The Board of Governors of…

DG

Dollar General

$85.50

0.59 (0.69%)

, DLTR

Dollar Tree

$94.61

-0.02 (-0.02%)

08:28
11/20/17
11/20
08:28
11/20/17
08:28
Recommendations
Dollar General, Dollar Tree analyst commentary  »

Dollar General price…

DG

Dollar General

$85.50

0.59 (0.69%)

DLTR

Dollar Tree

$94.61

-0.02 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 07

    Dec

OMI

Owens & Minor

$19.14

0.23 (1.22%)

08:27
11/20/17
11/20
08:27
11/20/17
08:27
Recommendations
Owens & Minor analyst commentary  »

Owens & Minor price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIZZ

National Beverage

$102.23

0.32 (0.31%)

08:26
11/20/17
11/20
08:26
11/20/17
08:26
Upgrade
National Beverage rating change  »

National Beverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$93.61

-0.86 (-0.91%)

08:25
11/20/17
11/20
08:25
11/20/17
08:25
Recommendations
AbbVie analyst commentary  »

AbbVie estimates raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$19.13

0.09 (0.47%)

08:25
11/20/17
11/20
08:25
11/20/17
08:25
Downgrade
Deutsche Bank rating change  »

Deutsche Bank downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AMZN

Amazon.com

$1,129.88

-7.41 (-0.65%)

, CVS

CVS Health

$70.68

0.42 (0.60%)

08:25
11/20/17
11/20
08:25
11/20/17
08:25
Recommendations
Amazon.com, CVS Health, Walgreens Boots Alliance, Cardinal Health, McKesson, AmerisourceBergen, Thermo Fisher, Henry Schein, Patterson Companies analyst commentary  »

Amazon disruption of…

AMZN

Amazon.com

$1,129.88

-7.41 (-0.65%)

CVS

CVS Health

$70.68

0.42 (0.60%)

WBA

Walgreens Boots Alliance

$71.25

-0.05 (-0.07%)

CAH

Cardinal Health

$57.51

0.09 (0.16%)

MCK

McKesson

$142.13

-0.57 (-0.40%)

ABC

AmerisourceBergen

$78.84

-1.09 (-1.36%)

TMO

Thermo Fisher

$190.17

-0.44 (-0.23%)

HSIC

Henry Schein

$69.12

-0.39 (-0.56%)

PDCO

Patterson Companies

$36.04

-0.03 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

  • 12

    Dec

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.